Head and Neck Cancers Coverage from Every Angle

Tipifarnib in HRAS-Mutant Head/Neck Squamous Cell Carcinomas

By: Kelly M. Hennessey, PhD
Posted: Wednesday, November 13, 2019

In a phase II trial, patients with head and neck squamous cell carcinomas that have HRAS mutations in at least 20% of their tumors experienced a high rate of response to tipifarnib, according to Alan L. Ho, MD, PhD, of Memorial Sloan Kettering Cancer Center. Updated data from the study were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Tipifarnib inhibits the enzyme farnesyl transferase, which is a key enzyme required for the proper function of HRAS.

As of the data cutoff date, a total of 21 patients were enrolled in the trial, all of whom had head/neck squamous cell carcinomas with HRAS missense mutations at a high variant allele frequency. All patients received a median of two prior treatments and experienced disease progression on their previous therapy.

In total, 18 patients were evaluable for efficacy, 10 of whom achieved an objective response rate (56%). Of the 18 patients, the median progression-free survival with tipifarnib was 6.1 months, compared with 2.8 months on their last therapy.

“This is another example of how understanding the genomics and biology of a disease can be leveraged to develop new and effective cancer therapies,” concluded Dr. Ho in an AACR press release. Dr. Ho acknowledged the small sample size and commented that a larger study of the agent in this patient population is necessary to confirm these early results.

Disclosure: The study was sponsored by Kura Oncology, which provided funding for the research team.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.